Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Ranbaxy Pharmaceuticals (Pty) Ltd, a Sun Pharma Company, 14 Lautre Road, Stormill Ext 1, Roodepoort, 1724, South Africa
CETIZAL 5 Film-coated Tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet: White, film-coated, scored, round, biconvex tablets debossed with ‘161’ on one side and ‘H’ on other side. |
Each film-coated tablet contains levocetirizine dihydrochloride 5 mg.
Contains sugar: Lactose monohydrate 65,71 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levocetirizine |
Levocetirizine, the ® enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose. |
| List of Excipients |
|---|
|
Tablet core: Colloidal anhydrous silica Film-coat: Titanium dioxide |
White opaque HDPE container with white opaque polypropylene, plastic cap containing 30 or 180 tablets.
Cold form blister pack comprising of cold formable laminated film with a backing of hard tempered plain silver aluminium foil containing 10 tablets.
Ranbaxy Pharmaceuticals (Pty) Ltd, a Sun Pharma Company, 14 Lautre Road, Stormill Ext 1, Roodepoort, 1724, South Africa
46/5.7.1/0329
06 August 2015
| Drug | Countries | |
|---|---|---|
| CETIZAL | Hong Kong, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
